Johns Hopkins Medicine Johns Hopkins Logo
make a gift
hopkins urology on you tube  twitter urology department at hopkins   facebook urology department at hopkins  blog urology department at hopkins  
                
   
John T. Isaacs, Ph.D. John T. Isaacs, Ph.D.
Professor of Oncology, Urology
Johns Hopkins Medical Institutions

Email:ISAACJO@jhmi.edu

INTERESTS

Molecular Biology of Prostate Cancer

EDUCATION

1971
    B.A., The Johns Hopkins University,
    Baltimore, Maryland (Natural Science Major)
1977
    Ph.D., Emory University School of Medicine,
    Dept. of Biochemistry Atlanta Georgia

ACADEMIC EXPERIENCE

  • 1977-80
      Postdoctoral Fellow,
      Department of Pharmacology and Experimental Therapeutics The Johns Hopkins University School of Medicine Baltimore, Maryland
  • 1980
      Assistant Professor of Oncology The Johns Hopkins University School of Medicine
  • 1980
      Assistant Professor of Urology The Johns Hopkins University School of Medicine
  • 1986
      Associate Professor of Oncology The Johns Hopkins University School of Medicine
  • 1986
      Associate Professor of Urology The Johns Hopkins University School of Medicine
  • 1993
      Professor of Oncology The Johns Hopkins University School of Medicine
  • 1993
      Professor of Urology The Johns Hopkins University School of Medicine
  • 1993
      Professor in Cell and Molecular Biology Graduate Program The Johns Hopkins University School of Medicine
  • 1998
      Co-Director Division of Experimental Therapeutics, The Johns Hopkins Oncology Center

PUBLICATIONS

 

  1. Free Access to abstracts at PubMed

    ARTICLES PUBLISHED IN PROFESSIONAL JOURNALS

       

    1. Isaacs, J. T. and Binkley, F. Glutathione Dependent Control of the Protein Disulfide Sulfhydryl Content of Subcellular Fractions of Hepatic Tissue. Biochim. Biophys. Acta 497:192-204, 1977.

    2. Isaacs, J. T. and Binkley, F. C-AMP Dependent Control of the Rat Hepatic Glutathione Disulfide/Sulfhydryl Ratio. Biochim. Biophys. Acta 498:29-33, 1977.

    3. Isaacs, J. T., Heston, W., Weissman, R. and Coffey, D. Animal Models of Hormone Sensitive and Insensitive Prostatic Adenocarcinomas: Dunning R-3327-H, HI and AT. Cancer Res. 38:4353-4359, 1978.

    4. Isaacs, J. T., McDermott, I. R. and Coffey, D. S. The Identification and Characterization of a New C19O3 Steroid Metabolite in the Rat Ventral Prostate: 5a -Androstane-3b, 6a-17b-Triol. Steroids 33:639-675, 1979.

    5. Isaacs, J. T., McDermott, I. R. and Coffey, D.S.Characterization of Two New Enzymatic Activities of the Rat Ventral Prostate: 5a- Androstane-3b,17b-Diol 6a-Hydroxylase and 5a-Androstane-3, b17b- Diol 7b- Hydroxylase. Steroids 33:675-752, 1979.

    6. Isaacs, J. T., Isaacs, W. B. and Coffey, D. S. Models for the Development of Non-Receptor Methods for Distinguishing Androgen Sensitive and Insensitive Prostatic Tumors. Cancer Res. 39:2652-2659, 1979.

    7. Isaacs, J. T. and Coffey, D. S. Animal Models in the Study of Prostatic Cancer. Cancer Detection and Prevention 2:587-599, 1979.

    8. Isaacs, J. T., McDermott, I. R. and Coffey, D. S. The Identification and Characterization of C19O3 Steroid Metabolites of 5a-Androstane-3b,17b-Diol Produced by the Canine Prostate: 5a-Androstane-3b,6a,17b-Triol and 5a-Androstane-3b,7b,17b-Triol. Steroids 35:139-156, 1980.

    9. . Isaacs, J. T., Isaacs, W. B., Wheaton, L. G. and Coffey, D. S. Differential Effects of Estrogen Treatment on Canine Prostatic Secretions. Invest. Urol. 17:495-498, 1980.

    10. Isaacs, J. T. and Coffey, D. S. Changes in Dihydrotestosterone Metabolism Associated with the Development of Canine Benign Prostatic Hyperplasia. Endocrinology 108:445-453, 1981.

    11. Isaacs, J. T., Yu, G. and Coffey, D. S. The Characterization of a Newly Identified, Highly Metastatic Variety of Dunning R-3327 Rat Prostatic Adenocarcinoma System: The MAT-LyLu Tumor. Invest. Urol. 19(1):20-23, 1981.

    12. Ehrlichman, R. J ., Isaacs, J. T. and Coffey, D. S. Differences in the Effects of Estradiol on Dihydrotestosterone Induced Prostatic Growth of the Castrate Dog and Rat. Invest. Urol. 18(6):466-470, 1981.

    13. Coffey, D. S. and Isaacs, J. T. The Control of Prostate Growth. Urology 17(3):17-24, 1981.

    14. Coffey, D. S. and Isaacs, J. T. Theory - Prostate Tumor Biology and Cell Kinetics. Urology 17(3):40-53, 1981.

    15. Isaacs, J. T. and Coffey, D. S. Adaptation vs. Selection as a Mechanism Responsible for the Relapse of Prostatic Cancer to Androgen Ablation Therapy as Studied in the Dunning R-3327-H Adenocarcinoma. Cancer Res. 41:5070-5075, 1981.

    16. Elder, J. S., Isaacs, J. T. and Walsh, P. C. Androgenic Sensitivity of the Gubernaculum Testis: Evidence for Hormonal- Mechanical Interactions in Testicular Descent. J. Urol. 127:170-176, 1982.

    17. Gesell, M. S., Brandes, M. J., Arnold, E. A., Isaacs, J. T., Udea, H., Millan, J. C. and Brandes, D. Retinoic Acid Binding Protein in Normal and Neoplastic Rat Prostate. The Prostate 3:131-138, 1982.

    18. Isaacs, J. T., Wake, N., Coffey, D. S. and Sandberg, A. A. Genetic Instability Coupled to Clonal Selection as a Mechanism for Tumor Progression in the Dunning R-3327 Rat Prostatic Adenocarcinoma System. Cancer Res. 42:2353-2361, 1982.

    19. Humphries, J. E. and Isaacs, J. T. Unusual Androgen Sensitivity of the Androgen-Independent Dunning R-3327-G Rat Prostatic Adenocarcinoma: Androgen Effect on Tumor Cell Loss. Cancer Res. 42:3148-3156, 1982.

    20. Wake, N., Isaacs, J. T. and Sandberg, A. A. Chromosomal Changes Associated with Progression of the Dunning R-3327 Rat Prostatic Adenocarcinoma System. Cancer Res. 42:4131-4142, 1982.

    21. Isaacs, J. T. Hormonally Responsive vs. Unresponsive Progression of Prostatic Cancer to Antiandrogen Therapy as Studied with the Dunning R-3327-AT and G Rat Prostatic Adenocarcinoma. Cancer Res. 42:5010-5014, 1982.

    22. Isaacs, J. T., Brendler, C. B. and Walsh, P. C. Changes in the Metabolism of Dihydrotestosterone in the Hyperplastic Human Prostate. J. Clin. Endo. Metab. 56:139-146, 1983.

    23. Isaacs, J. T. Changes in Dihydrotestosterone Metabolism and the Development of Benign Prostatic Hyperplasia in the Aging Beagle. J. Steroid Biochem. 18(No. 6):749-757, 1983.

    24. Berry, S. J. and Isaacs, J. T. Comparative Aspects of Prostatic Growth and Androgen Metabolism with Aging in the Rat versus the Dog. Endocrinology 114:511-520, 1984.

    25. Isaacs, J. T. Prostatic Structure and Function in Relation to the Etiology of Prostatic Cancer. The Prostate 4(4):351-366, 1983.

    26. Isaacs, J. T. The Timing of Androgen Ablation Therapy and/or Chemotherapy in the Treatment of Prostatic Cancer. The Prostate 5:1-17, 1984.

    27. Brendler, C. B., Isaacs, J. T., Follansbee, A. L. and Walsh, P. C. The Use of Multiple Variables to Predict Response to Endocrine Therapy in Carcinoma of the Prostate: A Preliminary Report. J. Urol. 131:694-700, 1984.

    28. Lowe, F. C. and Isaacs, J. T. Biochemical Methods for Predicting Metastatic Ability of Prostatic Cancer Utilizing the Dunning R-3327 Ra Prostatic Adenocarcinoma System as a Model. Cancer Res. 44:744-752, 1984.

    29. Isaacs, J. T. The Aging ACI/Seg versus Copenhagen Male Rat as a Model System for the Study of Prostatic Carcinogenesis. Cancer Res. 44:5785-5796, 1984.

    30. Isaacs, J. T. Antagonistic Effect of Androgen on Prostatic Cell Death. The Prostate 5:545-559, 1984.

    31. Brendler, C. B., Follansbee, A. and Isaacs, J. T. Discrimination between Normal, Hyperplastic and Malignant Human Prostatic Tissues by Enzymatic Profiles. J. Urol. 133: 495-501, 1985.

    32. Isaacs, J. T. The Progression of Breast and Prostatic Cancer. Reviews in Endocrine Related Cancer, Reviews on Endocrine-Related Cancer 20:13-18, 1985.

    33. Isaacs, J. T. Determination of the Number of Events Required for Mammary Carcinogenesis in the Sprague-Dawley Female Rat. Cancer Res. 45:4827-4832, 1985.

    34. Ellis, W. J. and Isaacs, J. T. The Effectiveness of Complete vs. Partial Androgen Withdrawal Therapy for the Treatment of Prostatic Cancer as Studied in the Dunning R-3327 System of Rat Prostatic Adenocarcinoma. Cancer Res. 45:6041-6050, 1985.

    35. Jarow, J. P., Isaacs, J. T. and Marshall, F. F. A Chicken Chorioallantoic Membrane Assay for the Evaluation of the Androgen Sensitivity of Prostatic Tissue. J. Urol. 135:1312-1318, 1986.

    36. Isaacs, J. T. Genetic Control of Resistance to Chemically Induced Mammary Carcinogenesis in the Rat. Cancer Res. 46:3958-3963, 1986.

    37. Isaacs, J.T., Isaacs, W.B., Feitz, W.F.J. and Scheres, J. Establishment and Characterization of Seven Dunning Rat Prostatic Cancer Cell Lines and their Use in Developing Methods for Predicting Metastatic Abilities of Prostatic Cancers. The Prostate 9:261-281, 1986.

    38. Schulze, H. and Isaacs, J. T. Biology and Therapy of Prostatic Cancer. Cancer Surveys 5:485-503, 1986.

    39. Matuo, Y., Nishi, N ., Matsui, S.-I., Sandberg, A.A., Isaacs, J. T.and Wada, F. Heparin Binding Affinity of Rat Prostatic Growth Factor in Normal and Cancerous Prostates: Partial Purification and Characterization of Rat Prostatic Growth Factor in the Dunning Tumor. Cancer Res. 47:188-192, 1987.

    40. Schulze, H., Isaacs, J. and Senge, T. Inability of Complete Androgen Blockade to Increase Survival of Patients with Advanced Prostate Cancer as Compared to Standard Hormonal Therapy. J. Urol. 137:909-911, 1987.

    41. Kyprianou, N. and Isaacs, J. T. Development of Androgen-Independent Tumor Cells and Their Implication for the Treatment of Prostatic Cancer. Urol. Res. 15:133-138, 1987.

    42. Kyprianou, N. and Isaacs, J. T. Biological Significance of Measurable Androgen Levels in the Rat Ventral Prostate Following Castration. The Prostate 10:313-324, 1987.

    43. Kyprianou, N. and Isaacs, J. T. Quantal Relationship Between Prostatic Dihydrotestosterone and Prostatic Cell Content: Critical Threshold Concept. The Prostate 11:41-50, 1987.

    44. Nishi, N., Matuo, Y., Matsui, S., Sandberg, A.A., Isaacs, J. T.and Wada, F. Isolation of a 41 Kilodalton Cytosol Protein from the Dunning Rat Prostatic Adenocarcinoma: Characterization as Depolymerized Actin Isomers. The Prostate 10:303-312, 1987.

    45. English, H.F., Santen, R.J. and Isaacs, J. T. Response of Glandular Versus Basal Rat Ventral Prostatic Epithelial Cells to Androgen Withdrawal and Replacement. The Prostate 11:229-242, 1987.

    46. Alexander, R.B., Isaacs, J. T.and Coffey, D.S. Tumor Necrosis Factor Enhances the In Vitro and In Vivo Efficacy of Chemotherapeutic Drugs Targeted at DNA Topoisomerase II in the Treatment of Murine Bladder Cancer. J. Urol. 138:427-429, 1987.

    47. Schalken, J. A., Ebeling, S. B., Isaacs, J. T., Treiger, B., Bussemakers, M. J. G., de Jong, M. E. M. and Van de Ven, W. J. M. Differential Hybridization Analysis Reveals Down-Regulation of Fibronectin m-RNA in Metastasizing Prostatic Cancer Cells. Cancer Res., 48:2042, 1988.

    48. Isaacs, J. T. Inheritance of a Genetic Factor from the Copenhagen Rat and the Suppression of Chemically Induced Mammary Adenocarcinogenesis. Cancer Res., 48:2204, 1988.

    49. Mohler, J. L., Partin, A. W., Isaacs, J. T. and Coffey, D. S. Prediction of Metastatic Potential in the Dunning R-3327 Adenocarcinoma Model by a New Grading System of Cell Motility. Cancer Res. 48:4312-4318, 1988.

    50. Henry, J. M. and Isaacs, J. T. Relationship Between Tumor Size and the Curability of Metastatic Prostatic Cancer by Surgery Alone or in Combination with Adjuvant Chemotherapy. J. Urol., 139:1119, 1988.

    51. Treiger, B. and Isaacs, J. T. Expression of a Transfected v-Harvey-Ras oncogene in a Dunning Rat Prostate Adenocarcinoma and the Development of High Metastatic Ability. J. Urol., 140:1580-1586, 1988.

    52. Kyprianou, N. and Isaacs, J. T. Activation of Programmed Cell Death in the Rat Ventral Prostate Following Castration. Endocrinology 122:552-562, 1988.

    53. Kyprianou, N. and Isaacs, J. T. Identification of a Cellular Receptor for Transforming Growth Factor b in Rat Ventral Prostate and its Negative Regulation by Androgens. Endocrinology 23:2124-2131, 1988.

    54. Isaacs, J. T. and Hukku, B. Nonrandom Involvement of Chromosome 4 in the Progression of Rat Prostatic Cancer. The Prostate 13:165-188, 1988.

    55. Kyprianou, N., English, H. and Isaacs, J. T. Activation of Ca2+Mg2+Dependent Endonuclease as an Early Event in Castration Induced Prostatic Cell Death. The Prostate, 13:103-117, 1988.

    56. Partin, A. W., Isaacs, J. T., Treiger, B. and Coffey, D. S. Early Cell Motility Changes Associated with an Increase in Metastatic Ability in Prostatic Cancer Cells Transfected with the v-Harvey-ras Oncogene. Cancer Res. 48:6050-6053, 1988.

    57. Carter, H. B. and Isaacs, J. T. Experimental and Theoretical Basis for Hormone Treatment of Prostatic Cancer. Seminars in Urology, VI:262-268, 1988.

    58. Matuo, Y., Nishi, N., Tanaka, H., Sasaki, I., Isaacs, J. T. and Wada, F. Production of IGF-II-Related Peptide by an Anaplastic Cell Line (AT-3) Established from the Dunning Prostatic Carcinoma of Rats. In Vitro Cell Dev. Biol. 24:1053-1056, 1988.

    59. Cooke, D. S., Quarmby, V. E., Mickey, D. D., Isaacs, J. T. and French, F. S. Oncogene Expression in Prostatic Cancer: Dunning R-3327 Rat Dorsal Prostatic Adenocarcinoma System. The Prostate, 13:263-273, 1988.

    60. Cooke, D. S., Quarmby, V. E. Petrusz, P., Mickey, D. D., Der, C. J. Isaacs, J. T. and French, F. S. Expression of ras Protooncogenes in the Dunning R-3327 Rat Prostatic Adenocarcinoma System. The Prostate, 13:273-289, 1988.

    61. Burgers, J. K., Marshall, F. F. and Isaacs, J. T. Synergistic Anti-Tumor Effects of Recombinant Human Tumor Necrosis Factor Plus VP-16 on Metastatic Renal Cell Carcinoma in a Xenograft Model. J. Urol. 142:160-164, 1989.

    62. Ramaekers, F., Verhagen, A., Isaacs, J. T., Feitz, F. J., Moesken, O., Schaart, G., Schalken, J. and Vooijs, G. P. Intermediate Filament Protein Expression and the Progression of Prostatic Cancer as Studied in the Dunning R-3327 Rat Prostatic Carcinoma System. The Prostate, 14:323-340, 1989.

    63. Henry, J. M. and Isaacs, J. T. Synergistic Enhancement of the Efficacy of the Bioreductively Activated Alkylating Agent RSU-1164 in the Treatment of Prostatic Cancer by Photodynamic Therapy. J. Urol. 142:165-170, 1989.

    64. Jarow, J. P. and Isaacs, J. T. Prostatic Growth Effects of Rat Urogenital Sinus and Human Prostatic Tissue in the Rat. The Prostate 14:301-308, 1989.

    65. Isaacs, J. T. and Coffey, D. S. Etiology of BPH. The Prostate, Supplement 2:33-58, 1989.

    66. English, H., Kyprianou, N. and Isaacs, J. T. Relationship Between DNA Fragmentation and Apoptosis in the Programmed Cell Death in the Rat Prostate Following Castration. The Prostate, 15:233-250, 1989.

    67. Isaacs, J. T. Relationship Between Tumor Size and Curability of Prostatic Cancer by Combined Chemohormonal Therapy. Cancer Res. 49:6290-6294, 1989.

    68. Kyprianou, N. and Isaacs, J. T. Expression of Transforming Growth Factor b in the Rat Ventral Prostate During Castration-induced Programmed Cell Death. Mol. Endocrinol. 3:1515-1522, 1989.

    69. Kyprianou, N. and Isaacs, J. T. "Thymineless" Death in Androgen-Independent Prostatic Cancer Cells. Biochem. Biophys. Res. Commun. 165:73-81, 1989.

    70. Kyprianou, N. and Isaacs, J. T. Relationship Between Metastatic Ability and ras Oncogene Expression in Rat Mammary Cancer Cells Transfected with the v-H-ras Oncogene. Cancer Res. 50:1449-1454, 1990.

    71. Carter, B., Pianpadosi, S. and Isaacs, J. T. Clinical Evidence for and Implications of the Multistep Development of Prostate Cancer. J. Urol. 143:742-746, 1990.

    72. Isaacs, J. T. The Importance of the Natural History of Benign Prostatic Hyperplasia in the Evaluation of Pharmacologic Intervention. The Prostate, Supplement 3:1-7, 1990.

    73. Steinberg, G.D. and Isaacs, J. T. Physiology of the Prostate. Contemporary Urology (May), p 54-68, 1990.

    74. Carter, B.S., Carter, H.B. and Isaacs, J. T. Epidemiologic Evidence Regarding Predisposing Factors to Prostatic Cancer. The Prostate 16:187-198, 1990.

    75. Matuo, Y., Nishi, N., Takasuka, H., Masuda, Y., Nishikawa, K.,Isaacs, J. T., Adams, P.S., McKeehan, W.L., Sato, G.H. Production and Significance of TGFb in AT-3 Metastatic Cell Line Established from the Dunning Rat Prostatic Adenocarcinoma. Biochem. Biophys. Res. Commun. 166:840-847, 1990.

    76. Carter, H.A. and Isaacs, J. T. Why Do Cells Metastasize? World J. Urol. 8:2-5, 1990.

    77. Kyprianou, N., English, H. and Isaacs, J. T. Programmed Cell Death During Regression of the PC-82 Human Prostate Cancer Following Androgen Ablation. Cancer Res. 50:3748-3752, 1990.

    78. Carter, B. and Isaacs, J. T. Predisposing Factor to Prostate Cancer. Reviews in Endocrine Related Cancer 34:13-18, 1990.

    79. Steinberg, G.D., Brendler, C.B., Ichikawa, T., Squire, R.A. and Isaacs, J. T. Characterization of an N-methyl-N-nitrosourea (MNU) Induced Autochthonous Rat Bladder Cancer Model. Cancer Res. 50:6668-6674, 1990.

    80. Ichikawa, T., Kyprianou, N. and Isaacs, J. T. Genetic Instability and the Acquisition of Metastatic Ability by Rat Mammary Cancer Cells Following v-H-ras Oncogene Transfection. Cancer Res. 50:6349-6357, 1990.

    81. Martikainen, P. and Isaacs, J. T. An Organ Culture System for the Study of Programmed Cell Death in the Rat Ventral Prostate. Endocrinol. 127:1268-1277, 1990.

    82. Isaacs, W.B.,Isaacs, J. T., Kyprianou, N, Burger, J.K., Alexander, R.B., Partin, A.W., Mohler, J.L., Marshall, F.F. and Coffey, D.S. New Approaches to the Evaluation of the Metastatic Ability of Renal Cancer and New Approaches to Chemotherapy. Eur. Urol., 18(Suppl. 2):33-35, 1990.

    83. Martikainen, P. and Isaacs, J. T. The Role of Calcium in the Programmed Death of Rat Prostatic Glandular Cells. The Prostate, 17:175-188, 1990.

    84. Martikainen, P., Kyprianou, N. and Isaacs, J. T. Effect of Transforming Growth Factor-ß1 on Proliferation and Death of Rat Prostatic Cells. Endo. 127:2963-2968, 1990.

    85. Tjota, A., Lee, N.T.,Isaacs, J. T., Kadohama, N. and Lee, C.L. Murine Monoclonal Antibodies Reactive with a Variety of Androgen Independent Dunning Rat Prostate Adenocarcinoma Sublines also Reactive with Human Prostate Adenocarcinoma. J. Urol. 146:205-212, 1990.

    86. Morton, R.A., Isaacs, J. T.and Isaacs, W.B. The Differential Effects of Growth Factor Antagonists on Neoplastic and Normal Prostatic Cells. The Prostate, 17:317-325, 1990.

    87. Newhall, K.R., Isaacs, J. T.and Wright, G.L. Jr. Dunning Rat Prostate Tumors and Cultured Cell Lines Fail to Express Human Prostate Carcinoma-Associated Antigens. The Prostate, 17:327-336, 1990.

    88. Kyprianou, N., English, H.F., Davidson, N.E., Isaacs, J. T. Programmed Cell Death During Regression of the MCF-7 Human Breast Cancer Following Estrogen Ablation. Cancer Res., 51:162-166, 1991.

    89. Kyprianou, N., Martikainen, P., and Isaacs, J. T. Programmed Cell Death of Normal and Malignant Prostatic Cells. Endo. Depent. Tumors, 69-81, 1991.

    90. Kyprianou, N., Alexander, R.B. and Isaacs, J. T. Activation of Programmed Cell Death by Recombinant Human Tumor Necrosis Factor Plus Topoisomerase II Targeted Drugs in L929 Tumor Cells. JNCI, 83:346-350, 1991.

    91. Ichikawa, T., Schalken, J.A., Ichikawa, Y., Steinberg, G.D. and Isaacs, J. T. H-ras Expression, Genetic Instability and Acquisition of Metastatic Ability by Rat Prostatic Cancer Cells Following v-H-ras Oncogene Transfection. The Prostate., 18:163-172, 1991.

    92. Isaacs, J. T. A Mammary Cancer Suppressor Gene and its Site of Action in the Rat. Cancer Res., 51:1591-1595, 1991.

    93. Steinberg, G.D., Brendler, C.B., Squire, R.A. and Isaacs, J. T. Experimental Intravesical Therapy for Superficial Transitional Cell Carcinoma in a Rat Bladder Tumor Model. J. Urol., 145:647-653, 1991.

    94. Ichikawa, T., Ichikawa, Y. and Isaacs, J. T. Genetic Factors and Suppression of Metastatic Ability of Prostatic Cancer. Cancer Res., 51:3788-3792, 1991.

    95. Björk, P., Isaacs, J. T.and Hartley-Asp, B. Estramustine Binding Protein (EMBP) in Rat R3327 Dunning Tumors: Partial Characterization and Effect of Hormonal Withdrawal, Hormonal Replacement, and Cytotoxic Treatment on its Expression. The Prostate 18:181-200, 1991.

    96. Martikainen, P., Kyprianou, N., Tucker, R.W. and Isaacs, J. T. Programmed Death of Non-Proliferating Androgen Independent Prostatic Cancer Cells. Cancer Res., 51:4693-4700, 1991.

    97. Kyprianou, N., Martikainen, P., Davis, L., English, H. and Isaacs, J. Programmed Cell Death as a New Target for Prostatic Cancer Therapy. Cancer Surveys 11, 265-278, 1991.

    98. Ichikawa, T., Ichikawa, Y. and Isaacs, J. T. Genetic Factors and Metastatic Ability of Prostate Cancer. Cancer Surveys 11, 35-42, 1991.

    99. Bussemakers, M.J.G.,Isaacs, J. T., Debruyne, F.M.J., Van de Ven, W.J.M., and Schalken, J.A. Oncogene Expression in Prostate Cancer. World J. Urol. 9:58-63, 1991.

    100. Juniewicz, P.E., Fetrow, N., Wolf, M.M., Young, E., Lamb, J. and Iasscs, J.T. Evaluation of Win 49,596, a Novel Steroidal Androgen Receptor Antagonist, in Animal Models of Prostate Cancer. The Prostate 18:105-115, 1991.

    101. Alles, A., Allen, K., Barrett, J.C., Buttyan, R., Columbano, A., Cope, F.O., Cope, E.A., Copelan, Duke, R.C., Farel, P.B., Gershenson, L.E., Goldgaber, D., Green, D.R., Honn, K.V., Hully, J.,Isaacs, J. T., Kerr, J.F.R., Krammer, Ph.D., Lockshin, R.A., Martin, D.P., McConkey, D.J., Michaelson, J., Schulte-Hermann, R., Server, A.C. Szende, B., Tomei, L.D., Tritton, T.R., Umansky, S.R., Valerie, K. and Warner, H.R. Apoptosis: A General Comment. FASEB J. 5:2127-2128, 1991.

    102. Lamb, J.C., English, H., Levandoski, P.L., Rhodes, G.R., Johnson, R.K., and Isaacs, J. T. Prostatic Involution in Rats Induced by a Novel 5a-Reductase Inhibitor, SK&F 105657: Role for Testosterone in the Androgenic Response. Endocrinology, 130:685-694, 1992.

    103. Ichikawa, T., Ichikawa, Y., and Isaacs. Genetic Factor and Suppression of Metastatic Ability of v-H-ras Transfected Rat Mammary Cancer Cells. Proc. Natl. Acad. Sci., USA 89:1607-1610, 1992.

    104. Redding, T.W., Schally, A.V., Radulovic, S., Milovanovic, S., Szepeshazi, K., and Isaacs, J. T. Sustained Release Formulations of LH-RH Antagonist SB-75 Inhibit Proliferation and Enhance the Apoptotic Cell Death of Human Prostate Carcinoma (PC-82) in Male Nude Mice. Cancer Res. 52:2538-2544, 1992.

    105. Pienta, K.J., Murphy, B.C., Isaacs, W.B., Isaacs, J. T.and Coffey, D.S. Effect of Pentosan, A Novel Cancer Chemotherapeutic Agent, on Prostate Cancer Cell Growth and Motility. The Prostate 20:233-241, 1992.

    106. Bussemakers, M.J.G., van Moorselaar, R.J.A., Giroldi, L.A., Ichikawa, T.,Isaacs, J. T., Takeichi, M., Debruyne, F.M.J. and Schalken, J.A. Decreased Expression of E-Cadherin in the Progression of Rat Prostatic Cancer. Cancer Res. 52:2916-2922, 1992.

    107. Ichikawa, T., Lamb, J.C., Christensson, P., Hartley-Asp, B., and Isaacs, J. T. The Anti-Tumor Effects of the Quinoline-3-Carboxamide, Linomide, on Dunning R-3327 Rat Prostatic Cancers. Cancer Res. 52:3022-3028, 1992.

    108. Passaniti, A.,Isaacs, J. T., Haney, J.A., Adler, S.W., Cujdik, T.J., Long, P.V., and Kleinman, H.K. Stimulation of Human Prostatic Carcinoma Tumor Growth in Athymic Mice and Control of Migration in Culture by Extracellular Matrix. Int. J. Cancer 51:318-324, 1992.

    109. Lamb, J.C., Levy, M.A., Johnson, R.K., and Isaacs, J. T. Response of Rat and Human Prostatic Cancers to the Novel 5a-Reductase Inhibitor, SK&F 105657, The Prostate 21:15-34, 1992.

    110. Armstrong, D.K.,Isaacs, J. T., Ottaviano, Y.L., and Davidson, N.E. Programmed Cell Death in an Estrogen-Independent Human Breast Cancer Cell Line, MDA-MB-468. Cancer Res. 52:3418-3424, 1992.

    111. Ichikawa, T., Ichikawa, Y., Hawkins, A.L., Griffin, C.A., Isaacs, W.B., Oshimura, M., Barrett, J.C., and Isaacs, J. T. Localization of Metastasis Suppressor Gene(s) for Prostatic Cancer to the Short Arm of Human Chromosome 11. Cancer Res. 52:3486-3490, 1992.

    112. Isaacs, J.T., Lundmo, P.I., Berges, R., Martikainen, P., Kyprianou, N., and English, H.F. Androgen Regulation of Programmed Death of Normal and Malignant Prostatic Cells. J. Andrology, 13:457-464, 1992.

    113. Vukanovic, J., Passaniti, A., Hirata, T., Traystman, R.J., Hartley-Asp, B. and Isaacs, J. T. Anti-Angiogenic Effects of the Quinoline-3-Carboxamide, Linomide. Cancer Res., 53:1833-1837, 1993.

    114. Levine, B., Huang, Q.,Isaacs, J. T., Reed, J.C., Griffin, D.E., and Hardwick, J.M. Conversion of Lytic to Persistent Alphavirus Infection by the bcl-2 Cellular Oncogene. Nature, 361:739-742, 1993.

    115. Isaacs, J. T. Hormonal Balance and the Risk of Prostatic Cancer. J. Cell Biochem., Supplement 16H:107-108, 1992.

    116. Rinker-Schaeffer, C.W., Isaacs, W.B. and Isaacs, J. T. Molecular and cellular markers for metastatic prostate cancer. Cancer and Metastasis Reviews 12:3-10, 1993.

    117. Berges, R. and Isaacs, J. T. Programming Events in the Regulation of Cell Proliferation and Death. Clinical Chemistry 39:2-8, 1993.

    118. Epner, D.E., Partin, A.W., Schalken, J.A.,Isaacs, J. T., and Coffey D.S. Association of Glyceraldehyde-3-phosphate Dehydrogenase Expression with Cell Mobility and Metastatic Potential of Rat Prostatic Adenocarcinoma. Cancer Res. 53:1995-1997, 1993.

    119. Berges, R.S., Furuya, Y., Jacks, T., English, H., and Isaacs, J. T. Cell Proliferation, DNA Repair, and p53 Function are not Required for Programmed Death of Prostatic Glandular Cells Induced by Androgen Ablation. Proc. Natl. Acad. Sci. (USA), 90:8910-8914, 1993.

    120. Isaacs, J. T. Role of Programmed Cell Death in Carcinogenesis. Environmental Health Perspective, 101 (Supplement 5):27-34, 1993.

    121. van Moorselaar, R.J.A., Ichikawa, T., Schaafsma, H.E., Jap, P.H.K.,Isaacs, J. T., van Stratum, P., Ramaekers, F.C.S., Debruyne, F.M.J., and Schalken, J.A. The Rat Bladder Tumor Model System RBT Resembles Phenotypically and Cytogenetically Human Superficial Transitional Cell Carcinoma. Urol. Res. 21:413-421, 1993.

    122. Furuya, Y. and Isaacs, J. T. Differential Gene Regulation During Programmed Death (Apoptosis) versus Proliferation of Prostatic Glandular Cells Induced by Androgen Manipulation. Endocrinol., 133:2660-2666, 1993.

    123. Isaacs, J. T. 5a-Reductase Inhibitors and Treatment of Benign Prostatic Hyperplasia. Drugs of Today, 29:335-342, 1993.

    124. Isaacs, J. T. Etiology of Benign Prostatic Hyperplasia. Eur Urol, 25(Supplement 1):6-9, 1994.

    125. Ichikawa, T., Nihei, N., Suzuki, H., Oshimura, M., Emi, M., Nakamura, Y., Hayata, I.,Isaacs, J. T., and Shimazaki, J. Suppression of Metastasis of Rat Prostatic Cancer by Introducing Human Chromosome 8. Cancer Res. 54:2299-2302, 1994.

    126. Isaacs, J. T. Advances and Controversies in the Study of Programmed Cell Death/Apoptosis in the Development and Therapy of Cancer Current Opinions in Oncology, 6:82-89, 1994).

    127. Furuya, Y. and Isaacs, J. T. Proliferation Independent Cell Death as a Therapeutic Target for Prostatic Cancer. Cancer Bulletin 46:173-180, 1994.

    128. Furuya, Y. and Isaacs, J. T. Proliferation Dependent versus Independent Programmed Cell Death of Prostatic Cancer Cells Involving Distinct Gene Regulation. The Prostate, 26:301-309, 1994.

    129. Armstrong, D.K., Ottaviano, Y.L., Kaufmann, S.H., Furuya, Y., Buckley, J.A., Isaacs, J. T.and Davidson, N.E. Programmed Cell Death of MDA-MB-468 Human Breast Cancer Cells: Characterization of Distinct Pathways Induced by Epidermal Growth Factor and Chemotherapeutic Drugs. Cancer Res., 54:5280-5283, 1994.

    130. Furuya, Y., Lundmo, P., Short, A.D., Gill, D.L., and Isaacs, J. T. The Role of Calcium, pH, and Cell Proliferation in the Programmed (Apoptotic) Death of Androgen-Independent Prostatic Cancer Cells Induced by Thapsigargin. Cancer Res., 54:6167-6175, 1994.

    131. Isaacs, J.T., Furuya, Y., and Berges, R. The Role of Androgen in the Regulation of Programmed Cell Death/Apoptosis in Normal and Malignant Prostatic Tissue. Seminars in Cancer Biology 5:391-400, 1994.

    132. Rinker-Schaeffer, C.W., Hawkins, A.L., Ru, N., Stoica, G., Griffin, C.A., Ichikawa, T., Barrett, J.C., and Isaacs, J. T. Differential Suppression of Mammary and Prostate Cancer Metastasis by Human Chromosomes 17 and 11. Cancer Res., 54:6249-6256, 1994.

    133. Rinker-Schaeffer, C.W., Partin, A.W., Isaacs, W.B., Coffey, D.S., and Isaacs, J. T. Molecular and Cellular Changes Associated With the Acquisition of Metastatic Ability by Prostatic Cancer Cells. The Prostate 26:249-265, 1994.

    134. Vukanovic, J., Hartley-Asp, B., and Isaacs, J. T. Inhibition of Tumor Angiogenesis and the Therapeutic Ability of Linomide Against Rat Prostatic Cancers. The Prostate 26:235-246, 1995.

    135. Furuya, Y., Lin, X.S., Walsh, J.C., Nelson, W.G., and Isaacs, J. T. Androgen Ablation Induced Programmed Death of Prostatic Glandular Cells Does Not Involve Recruitment into a Defective Cell Cycle or p53 Induction. Endocrinology 136:1898-1906, 1995.

    136. Berges, R.R., Vukanovic J., Epstein, J.I., CarMichel, M., Cisek, L., Johnson, D.E., Veltri, R.W., Walsh, P.C., and Isaacs, J. T. Implication of the Cell Kinetic Changes During the Progression of Human Prostatic Cancer. Clinical Cancer Research 1:473-480, 1995.

    137. Dong, J.-T., Lamb, P.W., Rinker-Schaeffer, C.W., Vukanovic, J., Isaacs, J. T.and Barrett, J.C. KAI1, a Metastasis Suppressor Gene for Prostate Cancer on Human Chromosome p11.2. Science 268:884-885, 1995.

    138. Vukanovic, J. and Isaacs, J. T. Linomide Inhibits Angiogenesis, Growth, Metastasis, and Macrophage Infiltration within Rat Prostatic Cancers. Cancer Res. 55:1499-1504, 1995.

    139. Vukanovic, J. and Isaacs, J. T. Human Prostatic Cancer Cells Are Sensitive to Programmed (Apoptotic) Death Induced by the Antiangiogenic Agent Linomide. Cancer Res. 55:3517-3520, 1995.

    140. Nihei, N., Ichikawa, T., Kawana, Y., Kuramochi, H., Kugo, H., Oshimura, M., Killary, A.M., Rinker-Schaeffer, C.W., Barrett, J.C., Isaacs, J. T.and Shimazaki, J. Localization of Metastasis Suppressor Gene(s) for Rat Prostatic Cancer to the Long Arm of Human Chromosome 10. Genes, Chromosomes & Cancer, 14:112-119, 1995.

    141. Rinker-Schaeffer, C.W., Hawkins, A.L., Su, S.L., Israeil, R.S., Griffin, C.A., Isaacs, J. T.and Heston, W.D.W. Localization and Physical Mapping of the Prostate Specific Membrane Antigen (PSM) gene to Human Chromosome 11. Genomics, 30:105-108, 1995.

    142. Furuya, Y., Isaacs, J. T.and Shimazaki, J. Induction of Programmed Death/Apoptosis in Androgen-dependent Mouse Mammary Tumor Cell Line (Shionogi Carcinoma 115) by Androgen Withdrawal. Jpn. J. Cancer Res., 86:1159-1165, 1995.

    143. Furuya, Y., Krajewski, S., Epstein, J.I., Reed, J.C. and Isaacs, J. T. Expression of bcl-2 and the Progression of Human and Rodent Prostatic Cancers. Clinical Cancer Research, 2:389-398, 1996.

    144. Ichikawa, T., Nihei, N., Kuramochi, H., Kawana, Y., Killary, A.M., Rinker-Schaeffer, C.W., Barrett, J.C.,Isaacs, J. T., Kugoh, H., Oshimura, M. And Shimazaki, J. Metastasis Suppressor Genes for Prostate Cancer. The Prostate 6:31-35, 1996.

    145. Denmeade, S.R., Lin, X.S. and Isaacs, J. T. Role of Programmed (Apoptotic) Cell Death During the Progression and Therapy of Prostate Cancer. The Prostate, 28:251-265, 1996.

    146. Dong, J-T., Rinker-Schaeffer, C.W., Ichikawa, T., Barrett, J.C. and Isaacs, J. T. Prostate Cancer - Biology of Metastasis and its Clinical Implications. World J. Urology, 14:182-189, 1996.

    147. Denmeade, S.R. and Isaacs, J. T. Programmed Cell Death (Apoptosis) and Cancer Chemotherapy. Cancer Control, 3:306-309, 1996.

    148. Rinker-Schaeffer, C.W., Wharam, J.F., Simons, J. and Isaacs, J. T. Development of a High-Efficiency Method for Gene Marking of Dunning Prostate Cancer Cell Lines with the Enzyme- 5b -Galactosidase. The Prostate, 29:60-64, 1996.

    149. Joseph, I.B.J.K., Vukanovic, J. and Isaacs, J. T. Anti-Angiogenic Treatment with Linomide as Chemoprevention for Prostate, Seminal Vesicle, and Breast Carcinogenesis in Rodents. Cancer Res., 56:3404, 1996.

    150. Joseph, I.B.J.K. and Isaacs, J. T. The Antiangiogenic agent, Linomide Inhibits TNF-aSecretion via Inhibition of its Synthesis. The Prostate, 29:183-190, 1996.

    151. Gao, A.C. and Isaacs, J. T. Expression of Homeobox Gene-GBX2 in Human Prostatic Cancer Cells. The Prostate, 29:395-398, 1996.

    152. Dong, J-T., Suzuki, H., Pin, S.S., Bova, S., Schalken, J.A., Isaacs, W.B., Barrett, J.C. and Isaacs, J. T. Down-Regulation of the KAI1 Metastasis Suppressor Gene During the Progression of Human Prostatic Cancer Infrequently Involves Gene Mutation or Allelic Loss. Cancer Res., 56:4387-4390, 1996.

    153. Gao, A.C., Lou, W., Dong, J-T. and Isaacs, J. T. CD44 is a Metastasis Suppressor Gene for Prostatic Cancer Located on Human Chromosome 11p13, Cancer Res., 57:846-849,1997.

    154. Dong, J-T, Isaacs, W.B. and Isaacs, J. T. Molecular Advances in Prostate Cancer. Current Opinion in Oncology, 9:101-107, 1997.

    155. Denmeade, S.R. and Isaacs, J. T. Prostate Cancer: Where are We and Where are We Going? Brit. J. Urol., 79(Suppl.)1:2-7, 1997.

    156. Dong, J-T., Isaacs, W.B., Barrett, J.C. and Isaacs, J. T. Genomic Organization of the Human KAI1 Metastasis Suppressor Gene. Genomics, 41:25-32, 1997.

    157. Isaacs, J. T. Molecular Markers for Prostate Cancer Metastasis. Am J. Path., 150:1511-1521, 1997.

    158. Bosland, M.C., Chung, L.W.K., Greenberg, N.M., Ho, S-m.,Isaacs, J. T., Lane, K., Peehl, D.M., Thompson, T.C., van Steenbrugge, G.J. and van Weerden, W.M. Recent Advances in the Development of Animal and Cell Culture Models for Prostate Cancer Research. Urol. Oncol., 2:99, 1997.

    159. Kawana, Y., Komiya, A., Ueda, T., Nihei, N., Kuramochi, H., Suzuki, H., Yatani, R., Imai, T., Dong, J-T., Imai, T., Yoshie, O., Barrett, J.C.,Isaacs, J. T., Shimazaki, J., Ito, H., and Ichikawa, T. Location of KAI1 on the Short Arm of Human Chromosome 11 and Frequency of Allelic Loss in Advanced Human Prostate Cancer. The Prostate 32:205-213, 1997.

    160. Joseph, I.B.J.K. and Isaacs, J. T.Potentiation of the Antiangiogenic Ability of Linomide by Androgen Ablation Involves Down-Regulation of Vascular Endothelial growth Factor in Human Androgen Responsive Prostatic Cancers. Cancer Res., 57:1054-1057, 1997.

    161. Isaacs, J. T. The R-3327 System of Rat Prostatic Cancers. Urol. Oncol., 4:115-116, 1997.

    162. Camoratto, A.M., Jani, J.P., Angeles, T.S., Maroney, A.C., Sanders, C.Y., Murakata, C., Neff, N.T., Vaught, J.L., Isaacs, J. T.and Dionne, C.A. CEP-751 Inhibits trk Receptor Tyrosine Acitivity In Vitro and Exhibits Anti-Tumor Activity. Inter. J. Cancer, 72:673-679, 1997.

    163. Hartley-Asp, B., Vukanovic, J., Joseph, I.B.J.K., Strandgarden, K., Polacek, J., and Isaacs, J. T. Anti-Angiogenic Treatment with Linomide as Adjuvant to Surgical Castration in Experimental Prostate Cancer. J. Urol., 158:902-907, 1997.

    164. Denmeade, S.R., Lou, W., Malm, J., Lilja, H., and Isaacs, J. T. Specific and Efficient Peptide Substrates for Assaying the Proteolytic Activity of Prostate Specific Antigen. Cancer Res., 57:4924-4930, 1997.

    165. Lin, X.S., Denmeade, S.R., Cisek, L. and Isaacs, J.T. Mechanism and Role of Growth Arrest in Programmed(Apoptotic) Death of Prostatic Cancer Cells Induced by Thapsigargin. The Prostate, 33:201-207, 1997.

    166. Joseph, I.B.J.K., Nelson, J.B., Denmeade, S.R., and Isaacs, J.T. Androgens Regulate Vasclar Endothelial Growth Factor Content in Normal and Malignant Prostatic Tissue. Clinical Cancer Res., 3:2507-2511, 1997.

    167. Gao, A.C., Lou, W., and Isaacs, J.T. Down-Regulation of Homeobox Gene GBX2 Expression Inhibits Human Prostate Cancer Clonogenic Ability and Tumorigenicity. Cancer Res., 58:1391-1394, 1998.

    168. Denmeade, S.R. and Isaacs, J.T. Enzymatic Activation of Prodrugs by Prostate Specific Antigen: Targeted Therapy for Metastatic Prostate Cancer. Cancer Jrnl, Scientific American, 4:15-21, 1998.

    169. Gao, A.C., Lou, W., Sleeman, J.P. and Isaacs, J.T. Metastasis Suppression by the Standard CD44 Isoform Does Not Require Binding of Prostate Cancer Cells to Hyaluronate. Cancer Res. 58:2350-2352, 1998.

    170. Denmeade, S.R., Nagy, A., Gao, J., Lilja, H., Schally, A.V., and Isaacs, J.T. Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen. Cancer Res. 58:2537-2540, 1998.

    171. George, D.J., Suzuki, H., Bova, G.S., and Isaacs, J.T. Mutational Analysis of the TrkA Gene in Prostate Cancer. The Prostate, 36:172-181, 1998.

    172. Dionne, C.A., Camoratto, A.M., Jani, J.P., Emerson, E., Neff, N., Vaught, J.L., Murakata, C., Djakiew, D., Lamb, J., Bova, S., George, D. and Isaacs, J.T. Cell Cycle-independent Death of Prostate Adenocarcinoma is Induced by the trk Tyrosine Kinase Inhibitor. Clin. Cancer Res, 4:1887-1889, 1998.

    173. Gao, J. and Isaacs, J.T. Development of an Androgen Receptor Null Model for Identifying the Site of Initiation for Androgen Stimulation of Proliferation and Suppression of Programmed (Apoptotic) Death of PC-82 Human Prostate Cancer Cells. Cancer Res.,58:3299-3306, 1998.

    174. Joseph, I.B.J.K. and Isaacs, J.T. The Dual Role of Macrophages in the Anti-Prostatic Cancer Response to One Class of Anti-Angiogenic Agents. JNCI, 90:1648-1653, 1998.

    175. Suzuki, H., Dong, J-T., Gao, A.C., Barrett, J.C., and Isaacs, J.T. Identification of the Rat Homologue of KAI1 and its Expression in Dunning Rat Prostate Cancers. The Prostate,37:253-260, 1998.

    176. Gao, A.C., Lou, W., Ichikawa, T., Denmeade, S.R., Barrett, J.C.,and Isaacs, J.T. Suppression of the Tumorigenicity of Prostatic Cancer Cells by Gene(s) Located on Human Chromosome 19p13.1-13.2. The Prostate, 38:46-54, 1999.

    177. Tombal, B., Denmeade, S.R., and Isaacs, J.T. Assessment and Validation of a Microinjection Method for Kinetic Analysis of [Ca2+]i in Individual Cells Undergoing Apoptosis. Cell Calcium, 25:19-28, 1999.

    178. Nihei, N., Ohta, S., Kuramochi, H., Kugoh, H., Oshimura, M., Barrett, J.C., Isaacs, J.T., Igarashi, T., Ito, H., Masai, M., Ichikawa, Y., and Ichikawa, T. Metastasis Suppressor Gene(s) for Rat Prostate Cancer on the Long Arm of Human Chromosome 7. Gene, Chromosomes & Cancer, 24:1-8,1999.

    179. Gao, J., Tombal, B., and Isaacs, J.T. Rapid In Situ Hybridization Technique for Detecting Malignant Mouse Cell Contamination in Human Xenograft Tissue from Nude Mice and In Vitro Cultures from such Xenografts. The Prostate, In press, 1999.

    BOOK CHAPTERS

       

    1. Coffey, D. S., Isaacs, J. T. and Weissman, R. M. Animal Models for the Study of Prostatic Cancer. IN: Prostatic Cancer (Murphy, G., Ed.), PSG Publishing Co., MA., pp. 89-100, 1979.

    2. Isaacs, J. T., Scott, W. W. and Coffey, D. S. New Biochemical Methods to Determine Androgen Sensitivity of Prostatic Cancer: The Relative Enzymatic Index. IN: Prostate Cancer and Hormone Receptors, Alan R. Liss, Inc., New York, pp. 133-144, 1979.

    3. Coffey, D. S. and Isaacs, J. T. Prostate Cancer. A Series of Workshops on the Biology of Human Cancer, Report No. 9 (Coffey, D. S. and Isaacs, J. T., Eds.), International Union Against Cancer, Geneva, Oct. 23-26, 1979.

    4. Isaacs, J. T. and Coffey, D. S. Androgenic Control of Prostatic Growth: Regulation of Steroid Levels. IN: Prostate Cancer. Workshop on the Biology of Human Cancer, Report No. 9 (Coffey, D. S. and Isaacs, J. T., Eds.), International Union Against Cancer, Geneva, Oct. 23-26, pp. 112-125, 1979.

    5. Weissman, R. M., Scott, W. W., Isaacs, J. T. and Coffey, D. S. Concepts Related to Prostatic Cancer as Revealed by a Study of the Dunning R-3327 Prostatic Adenocarcinoma. IN: Advances in Medical Oncology, Research and Education, Vol. 11, Clinical Cancer Principle Sites 2 (Wilkinson, P. M., Ed.), Pergamon Press, Oxford, pp. 313-321, 1979.

    6. Isaacs, J. T. and Coffey, D. S. Spontaneous Animal Models for Prostatic Cancer. IN: Prostate Cancer: Workshop on the Biology of Human Cancer, Report No. 9 (Coffey, D. S. and Isaacs, J. T., Eds.), International Union Against Cancer, Geneva, Oct. 23-26, pp. 195-217, 1979.

    7. Coffey, D. S. and Isaacs, J. T. Experimental Concepts in the Design of New Treatments for Human Prostatic Cancer. IN: Prostate Cancer: Workshop on the Biology of Human Cancer, Report No. 9 (Coffey, D. S. and Isaacs, J. T., Eds.), International Union Against Cancer, Geneva, Oct. 23-26, pp. 233-263, 1979.

    8. Isaacs, J. T. and Coffey, D. S. Requirements for an Idealized Animal Model of Prostatic Cancer. IN: Model for Prostatic Cancer (Ablin, R. J. and Nieburgs, H. E., Eds.), Alan R. Liss, N. Y., pp. 379-391, 1980.

    9. Isaacs, J. T., Weissman, R. M., Coffey, D. S. and Scott, W. W. Concepts in Prostatic Cancer Biology: Dunning R-3327-H, HI and AT Tumors. IN: Models for Prostatic Cancer (Ablin, R. J. and Nieburgs, H. E., Eds.), Alan R. Liss, N. Y., pp. 311-323, 1980.

    10. Isaacs, J. T. and Coffey, D. S. Androgen Metabolism in the Prostate: New Concepts Related to Normal and Abnormal Growth. IN: Klinische und Experimentelle Urologie Band 3 - Antihormone Bedeutung in der Urologie (Altwein, J. E., Bartsch, G. and Jacobi, G. H., Eds.), W. Zuckschweidt Verlag Munchen, Munich, pp. 3-20, 1981.

    11. Isaacs, J. T., Barrack, E. R., Isaacs, W. B. and Coffey, D. S. The Relationship of Cellular Structure and Function: The Matrix System. IN: Prostatic Cell: Structure and Function (Murphy, G., Ed.), Alan R. Liss, Inc., N. Y., pp. 1-24, 1981.

    12. Isaacs, J. T. and Coffey, D. S. Animal Models in the Study of Prostatic Cancer. IN: Prostatic Cancer (Ablin, R., Ed.), Marcel Dekker, Inc., N. Y., pp. 61-72, 1981.

    13. Isaacs, J. T. and Coffey, D. S. Animal Models for the Study of Benign Prostatic Hyperplasia and Prostatic Cancer. IN: Scientific Foundations of Urology (Williams, D. I. and Chisholm, S. D., Eds.), William Heinemann Medical Books, Ltd., England, pp. 743-754, 1982.

    14. Isaacs, J. T. Mechanisms for and Implications of the Development of Heterogeneity of Androgen Sensitivity in Prostatic Cancer. IN: Tumor Cell Heterogeneity: Origins and Implications. Proceedings of the Fourth Annual Bristol-Myers Symposium on Cancer Research, Academic Press, Inc., N. Y., Vol. 4, pp. 99-114, 1982.

    15. Isaacs, J. T. Tumor Cell and Host Factors in the Development of Resistance to Hormonal Therapy. IN: Drug and Hormone Resistance in Neoplasia, Vol. I, Basic Concepts (Bruchovsky, N. and Goldie, J. H., Eds.), CRC Press, Boca Raton, Florida, pp. 139-156, 1982.

    16. Isaacs, J. T. and Coffey, D. S. Model Systems for the Study of Prostatic Cancer. IN: Cancer and the Prostate (Murphy, G. P., Ed.), Clinics in Oncology 2, pp. 479-498, 1983.

    17. Isaacs, J. T. Genetic Instability Coupled to Clonal Selection as a Mechanism for the Progression of Prostatic Cancer. IN: Cancer: Etiology and Prevention (Crispin, R., Ed.), Elsevier-North Holland, pp. 79-90, 1983.

    18. Isaacs, J. T. Common Characteristics of Human and Canine Benign Prostatic Hyperplasia. IN: New Approaches to the Study of Benign Prostatic Hyperplasia (Kimball, F. A., Ed.), Alan R. Liss, Inc., N. Y., pp. 217-234, 1984.

    19. Isaacs, J. T. Mechanisms for Resistance of Prostatic Cancers to Androgen Ablation Therapy. IN: Regulation of Androgen Action: Proceedings of an International Symposium, Montreal 1984 (Bruchovsky, N., Chapdelaine, A. and Neuman, F., Eds.), Congressdruck R. Bruchner, Berlin, pp. 71-76, 1985.

    20. Isaacs, J. T. New Principles in the Management of Metastatic Prostatic Cancer. IN: EORTC Genitourinary Group Monograph 2, Part A. Therapeutic Principles in Metastatic Prostatic Cancer. Progress in Clinical and Biological Research 185(A):383-406, 1985.

    21. Isaacs, J. T. Clonal Heterogeneity Within Breast Cancer and its Significance for Prognosis. IN: Breast Cancer: Treatment and Prognosis. (Stoll, B. A., Ed.), Blackwell Scientific Publications, Ltd., London, 1986.

    22. Isaacs, J. T. Control of Cell Proliferation and Cell Death in the Normal and Neoplastic Prostate. IN: Benign Prostatic Hyperplasia, Volume II (C. H. Rodgers, D. S. Coffey, G. Cunha, J. T. Grayhack, F. Hinman, Jr. and R. Horton, Eds.), NIH Publication No. 87-2881, pp. 85-94, 1987.

    23. Isaacs, J. T. Development and Characteristics of the Available Animal Model Systems for the Study of Prostatic Cancer. IN: Current Concepts and Approaches to the Study of Prostate Cancer. Progress in Clinical and Biological Research, Vol. 20 (Coffey, D.S., Bruchovsky, N., Gardner, W.A., Jr., Resnick, M.I. and Karr, J.P. Eds.), Alan R. Liss, New York, 1987, pp. 513-576.

    24. Schulze, H., Isaacs, J. T. and Coffey, D. S. A Critical Review of Total Androgen Ablation in the Treatment of Prostate Cancer. IN: Prostate Cancer, Part A. Research, Endocrine Treatment, and Histopathology. Progress in Clinical and Biological Research, Vol. 243A, (Murphy, G., Khoury, S., Kuss, R., Chatelain, C. and Denis, L., eds.), Alan R. Liss, New York, pp. 1-21, 1987.

    25. Isaacs, J. T., Schulze, H. and Coffey, D. S. Development of Androgen Resistance in Prostatic Cancer. IN: Prostate Cancer, Part A. Research, Endocrine Treatment, and Histopathology. Progress in Clinical and Biological Research, Vol. 243A, (Murphy,G., Khoury, S., Kuss, R., Chatelain, C. and Denis, L., eds.), Alan R. Liss, New York, pp. 21-23, 1987.

    26. Isaacs, J. T. Complete vs. Partial Androgen Withdrawal Therapy for the Treatment of Prostatic Cancer. IN: Proceedings of the 1st International Congress on Cancer and Hormones, Rome. Parthenon Publishing Ltd., 1987.

    27. Isaacs, J. T. and Kyprianou, N. Biological Basis for Combined Chemo-Hormonal Therapy for Prostatic Cancer. IN: New Trends in Diagnosis and Treatment of Prostatic Cancer. Proceedings of the 1st International Symposium on Advances in Urologic Oncology, San Remo, Italy, Jan. 22-24, Acta Medica Edizioni e Congressi , pp. 241-255, 1987.

    28. Isaacs, J. T. Prevention of Prostatic Carcinogenesis - Is It Realistic? IN: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. (Coffey, D.S., Resnick, M., Dorr, A.A. and Karr, J., Eds.), Plenum Press, New York, pp. 25-34, 1988.

    29. Isaacs, J. T. Epidemiology and Natural History of Benign Prostatic Hyperplasia. IN: Prostate et Alpha - Bloquants. Excerpta Medica, Amsterdam, pp. 1-10, 1988.

    30. Isaacs, J. T. Clonal Heterogeneity and its Implications. IN: Biology of Endocrine Treatment in Cancer (Stoll, B.A., ed.), Blackwell Scientific Publications, Ltd., London, 1989.

    31. Isaacs, J. T. Schulze, H. and Kyprianou, N. Experimental Studies on the Optimal Therapy for Prostatic Cancer. IN: The Prostate (Fitzpatrick and Krane, eds.), Churchill Livingstone, London, pp. 33-40, 1989.

    32. Schulze, H., Oesterling, J. E., Isaacs, J. T. and Coffey, D. S. Hormonal Therapy of Prostate Cancer: Limitations in the Total Androgen Ablation Concept. IN: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. (Coffey, D.S., Resnick, M.I., Dorr, F.A. and Karr, J.P., Eds.), Plenum Press, N.Y., pp. 215-224, 1988.

    33. Isaacs, J. T. Stem Cell Organization of the Prostate and the Development of Benign Prostatic Hyperplasia. IN: New Developments in Biosciences - Prostatic Hyperplasia, Etiology, Surgical and Conservative Management. (Ackerman, R., and Schroder, F.H., Eds.), Walter de Gruyter, Berlin, pp. 23-34, 1989.

    34. Isaacs, J. T. and Kyprianou, N. Biological Basis of Chemohormonal Therapy for Prostatic Cancer. IN: Urological Oncology (Lepor, H. and Ratliff, T., Eds.), Kluwer Academic Publishers, Boston, pp. 177-194, 1989.

    35. Isaacs, J. T. Therapeutic Implications of the Tumor Biology of Prostatic Cancer. IN: New Aspects in the Regulation of Prostatic Function (Aumuller, G., Krieg, M. and Senge, Th., Eds.), W. Zuckschwerdt Verlag, Munchen, pp. 45-58, 1989.

    36. Carter, H. B. and Isaacs, J. T. Overview of Hormonal Therapy for Prostate Cancer. IN: Uro-Oncology (Wirth, D., Ed.), Alan R. Liss, Inc., N.Y. (In press), 1989.

    37. Schulze, H. and Isaacs, J. T. Development of Hormone Refractory Tumors: Adaptation vs. Clonal Selection. IN: Hormone-Related Malignant Tumors (L. Beck, Grundmann E., Acherman R., Röher H, eds), Springer-Verlag, Berlin, pp. 153-162, 1990.

    38. Kyprianou, N., Martikainen, P. and Isaacs, J. T. Therapeutic Approaches to Activating Programmed Cell Death of Androgen-Independent Prostatic Cancer Cells. IN: Molecular and Cellular Biology of Prostate Cancer (Karr, J.P., Tindall, D.J., Coffey, D.S. and Smith, R.G., Eds.), pp. 51-64, 1991.

    39. Isaacs, J. T., Isaacs, W.B., and Schalken, J. Comparative Aspects of Multistep Prostatic Carcinogenesis in Humans and Rodents. IN: Comparative Molecular Carcinogenesis (Klein-Szanto, A., Anderson, M., Barrett, J.C. and Slaga, T.J., eds), John Wiley & Sons, Inc., New York pp. 261-288, 1992.

    40. Steinberg, G.D. and Isaacs, J. T. Pharmacological Approaches to the Management of Metastatic Prostatic Cancer. IN: Cancer Chemotherapy/Frontiers in Pharmacology (Hickman J. and Tritton, T., eds) Blackwell, London pp. 322-343, 1993.

    41. Isaacs, J. T. Prostatic Cancer: An Age-old Problem In Underlying Molecular, Cellular and Immunological Factors in Age-Related Cancers (ed Yang, S.S. and Warner, H.). Plenum Publishing Corporation, New York, pp. 167-184, 1993.

    42. Furuya, Y., Berges, R.S., Lundmo, P. and Isaacs, J. T. Proliferation Independent Activation of Programmed Cell Death as a Novel Therapy for Prostate Cancer. In Apoptosis (Mihich E. and Schimke R., eds). Plenum Publishing Corporation, New York, pp. 137-156, 1994.

    43. Isaacs, J. T. Role of Androgens in Prostatic Cancer. Vitamins and Hormones, Academic Press, Inc., vol. 49, pp. 433-502, 1994.

    44. Furuya, Y., Berges, R., Lundmo, P., Isaacs, J. T. Cell Proliferation, p53 Gene Expression, and Intracellular Calcium in Programmed Death: Prostate Model. IN: The Molecular Basis of Apoptosis in Disease, Cold Spring Harbor Laboratory Press, pp. 231-252, 1994.

    45. Ichikawa, T., Nihei, N., Suzuki, H., Oshimura, M., Emi, M., Nakamura, y., Hayata, I., Isaacs, J. T. and Shimazaki, J. Localization of Metastasis Suppressor Gene(s) for Prostatic Cancer to Human Chromosomes. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH. Eds, Kyoichi Imai, Jun Shimazaki and James P. Karr, Adenine Press, pp. 151-156, 1994.

    46. Scher, H.I., Isaacs, J. T., Fuks, Z., Walsh, P.C. Prostate. Clinical Oncology. Abeloff, M.D., Armitage, J.O., Lichter, A.S. and Niederhuber, J.E., eds). Churchill Livingston, New York, Edinburgh, London, Milbourne, Tokyo, pp. 1439-1472, 1995.

    47. Lin, X.S., Denmeade, S.R. and Isaacs, J. T. The Genetics of Programmed (Apoptotic) Cell Death. Imperial Cancer Research Fund, London, UK. Cancer Surveys, 25:173-194, 1995.

    48. Isaacs, J. T. Role of androgens in Normal and Malignant Growth of the Prostate. IN: Pharmacology, Biology and Clinical Applications of Androgen. Current Status and Future Prospects. Bhasin, S., Gabelnick, H.L., Spieler, J.M., Swerdloff, R.S., Wang, C. And Kelly, C, eds). Wiley-Liss, pp. 95-101, 1996.

    49. Denmeade, S.R. and Isaacs, J. T. Activation of Programmed (Apoptotic) Cell Death for the Treatment of Prostate Cancer. IN: Advances in Pharmacology, Academic Press, Inc., 35:281-306, 1996.

    50. Isaacs, J. T., Cussenot, O., Jankevicius, H., Klocler. J., Kubota, Y., Morgia, G., Rennie, P., and Schmitz-Dräger. Growth Regulation of Normal and Malignant Prostatic Cells. IN: First International Consultation on Prostate Cancer. Murphy, G., Denis, L., Chatelain,C., Griffiths, K., Khoury, S., and Cockett, A.T., eds). Proceedings, pp.31-81, 1996.

    51. Isaacs, W.B. and Isaacs, J. T. Molecular Genetics of Prostate Cancer Progression. IN: Principles and Practice of Genitourinary Oncology. Lippincott, J.B., pp.403-408, 1997.

    52. Denmeade, S.R., McCloskey, D.E., Joseph, I.B.J.K., Hahm, H.A., Isaacs, J. T. and Davidson, N.E. Apoptosis in hormone - responsive malignancies. In: Advances in Pharmacology, Ed. by Kaufmann, S.H., Academic Press, Inc., San Diego, pp 553-583, 1997

    53. Denmeade, S.R., and Isaacs, J.T. Programmed (Apoptotic) Cell Death and Prostate Cancer. In: Apoptosis and Cancer. Seamus J. Martin (ed.) Basel: Karger Landes Systems, pp 265, 1997.

    54. Gao, A.C., and Isaacs, J.T. The Molecular Basis of Prostate Carcinogenesis. Molecular Basis of Human Cancer. Edited by Coleman, W.B. and Tsongalis, G.J. The Human Press Inc. Totowa, N.J., In press, 1999.

    55. Isaacs, J.T. The Biology of Hormone Refractory Prostate Cancer: Why Does It Develop? Urologic Clinics of North America. Edited by W.B. Saunders Company. Philadelphia, PA, In press, 1999.

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

  • American Association for Cancer Research

  • American Association for the Advancement of Science

  • American Society of Andrology

  • American Urological Society

  • Endocrine Society

  • European Society for Urological Oncology and Endocrinology

  • Society for Basic Urologic Research

  • Urological Research Society

  • Society for Experimental Biology and Medicine

AWARDS & HONORS

  • 1977   Sigma Xi Award for the best research by an Emory Graduate Student 1976-77

  • 1981   Invited Speaker at the 4th Bristol-Myers Symposium on Tumor Cell Heterogeneity, Baltimore, MD

  • 1983   Invited Symposium Speaker at the 74th Annual Meeting of the American Association for Cancer Research, San Diego, CA

  • 1986   Invited Keynote Speaker at the 5th Congress of the European Society for Urological Oncology and Endocrinology, Edinburgh, Scotland

  • 1988   Invited Speaker at Gordon Conference on Reproductive Biology, Brewster, NH

  • 1989   Vice President of the Society for Basic Urologic Research

  • 1989   Invited Speaker at Gordon Conference on Hormonal Carcinogenesis

  • 1990   Invited Speaker - 1st Italian-American Synposium on Immunobiological Aspects of Oncology, New York, NY

  • 1990   President of the Society for Basic Urologic Research

  • 1990   Visting Research Professor, Harvard Urology Program

  • 1990   Invited Speaker at Gordon Conference on Cancer Chemotherapy, NH

  • 1991   Invited Speaker of the Fourth International Symposium of the Foundation For Promotion of Cancer Research, Tokyo, Jn

  • 1991   Invited Speaker - World Congress of Urology, Seville, Spain

  • 1991   Invited Guest Editor for Volume 11 of Cancer Surveys on Prostatic Cancer

  • 1992   Invited Chairperson for Symposium on Programmed Cell Death at the 83rd Annual Meeting of the American Association for Cancer Research, San Diego, CA

  • 1992   Invited Speaker at Gordon Conference on Cancer, New Port, RI

  • 1992   Invited Speaker at the Keystone Symposium on Breast and Prostate Cancer, Tahoe, CO

  • 1992   Invited Speaker at the Keystone Symposium on Chemoprevention and Early Malignant Lesions of the Prostate, Scottsdale, AZ

  • 1992   Invited Symposium Speaker at the 11th Joint Meeting British Endocrine Societies, Harrogate, UK

  • 1992   Invited Speaker at the 5th International Conference on Carcinogenesis and Risk Assessment, Austin, Texas

  • 1992   Invited Speaker at the NIEHS Symposium on "Cell Proliferation and Chemical Carcinogenesis", Durham, North Carolina

  • 1992   Invites Speaker at the Japanese-American (NIEHS) Joint Conference on Hormonal Carcinogenesis, Kona, Hawaii

  • 1992   Invited Speaker at the Japanese-American (NCI) Joint Conference on Growth Factors and Cancer, Maui, Hawaii

  • 1993   Invited Speaker at American Association for Cancer Research Symposium on Cancer Genetic and Differentiation, Hilton Head, South Carolina

  • 1993   Chairman of Poster-Discussion Section at the 88th Annual Meeting of the American Urological Association, San Antonio, Texas

  • 1993   Chairman of Mini-Symposium on Programmed Cell Death at the 84th Annual Meeting of the American Association for Cancer Research, Orlando, Florida

  • 1993   Invited Speaker at Annual Meeting of the British Endocrine Society, Harogate, U.K.

  • 1993   Co-Chairman and Speaker at Keystone Symposium on Breast and Prostate Cancer II, Tahoe, Colorado

  • 1993   Invited Speaker at Perzcoller Foundation Symposium on Programmed Cell Death, Trento, Italy

  • 1993   Organizer and Speaker at the American Association for Cancer Research Special Conference in Cancer Research; Cell Death on Cancer and Development, Chatham, Mass.

  • 1993   Invited Speaker at Scandinavian Congress of Urology, Oslo, Norway

  • 1993   Foundation for the Cure of Prostate Cancer (CapCure), 1st Annual Research Award, Washington, DC

  • 1994   Invited Speaker at Keystone Symposium on Molecular Genetic of Progression and Metastasis, Big Sky, Montana

  • 1994   Invited Speaker at Symposium on Prostatic Cancer, (Danish Urological Society) Aarhus, Denmark

  • 1994   Invited Speaker at Norwegian Institute Urologic Meeting on Benign Prostatic Hyperplasia, Oslo, Norway

  • 1994   Invited Speaker at 47th Annual MD Anderson Symposium in Cancer, Houston, TX

  • 1994   Invited Speaker at American Association for Cancer Research Special Conference on Translational Research, Ashville, N.C.

  • 1994   Invited Speaker at American Association for Cancer Research Special Conference on Prostatic Cancer, Palm Spring, CA

  • 1994   Foundation for the Cure of Prostate Cancer (Capcure) 2nd Annual Research Award, Washington, DC

  • 1994   Invited Speaker at Ciba Foundation Symposium on Programmed Cell Death, London, U.K.

  • 1994   Invited Speaker at Annual Meeting of British Pharmacology Society, Manchester, U.K.

  • 1995   Burroughs Welcome Visiting Professor at University of Vermont Medical School

  • 1995   Invited Speaker of American Association for Cancer Research for Japanese American Meeting, Maui, Hawaii

  • 1995   Chairman of the 11th Guy Forbeck Foundation Symposium, "Role of Programmed (Apoptotic) Cell Death in Treatment and Prevention of Cancer", Hilton Head, S.C.

  • 1995   Keynote Speaker at the 89th Annual Meeting of the Japanese Urological Association, Chiba-Japan

  • 1995   Keynote Speaker (George B. Koelle Lecture) - Programmed Cell Death-Apoptosis as a Therapeutic Target for Prostate Cancer, Mid-Atlantic Pharmacology Society

  • 1995   Invited Speaker at the First World Congress on Urological Research Organized by the ESUOE and SBUR, Rotterdam, The Netherlands

  • 1995   Invited Speaker at Gordon Conference on Calcium, NH

  • 1995   Invited Speaker at the 5th Annual Fall Symposium of the Society for Basic Urologic Research (SBUR)

  • 1995   Invited Symposium Speaker at the 86th Annual Meeting of the American Association for Cancer Research

  • 1995   Foundation for the Cure of Prostate Cancer (CapCure) 3rd Annual Research Award

  • 1996   Keynote Address, Student Research Forum, University of Kansas Medical Center

  • 1996   Invited Speaker at the XIth Ovarian Workshop: Ovarian Cell Growth, Apoptosis and Cancer, London Ontario

  • 1996   Invited Speaker at the Robert Steele Foundation Symposium on the Biology of Metastasis, NY,NY

  • 1996   Foundation for the Cure of Prostate Cancer (CapCure) 4th Annual Research Award

  • 1996   Invited Speaker at the 7th Prouts Neck Meeting on Prostate Cancer, Black Point Inn, Maine

  • 1996   Invited Speaker at the 1st Donald S. Coffey Research Conference/Pfizer - West Palm Beach, Florida

  • 1996   Keynote Speaker at the International Conference on PSA and Prostatic Disease sponsored by Euro/DPC Limited, Wales, U.K.

  • 1996   Session Chairman for the 1st International Consultant on Prostate Cancer, Monte Carlo, Monaco

  • 1997   Invited Speaker at Progress and Prospects for Chemoprevention of Prostate Cancer, Beaver Creek, Colorado

  • 1997   Co-Chairman of the Cambridge Symposium on Genetic Approaches to Breast and Prostate Cancer, Tahoe, California

  • 1997   Invited Speaker at the Symposium on Metastasis, Invasion, and Angiogenesis: Mechanisms and Therapeutic Strategies, 88th Annual Meeting of the American Association for Cancer Research, San Diego, California

  • 1997   Link Visiting Professor, Royal Marsden Cancer Hospital, London, United Kingdom

   CONTACT INFORMATION

 





    © The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
    Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287